Drug Type Drug conjugates |
Synonyms DDC2 PARP-ER(Nuvation Bio), NUV-1176 |
Target |
Action antagonists, inhibitors |
Mechanism ERs antagonists(Estrogen receptors antagonists), PARP inhibitors(Poly (ADP-Ribose) polymerase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Preclinical | United States | - | |
Ovarian Cancer | Preclinical | United States | - |